CALZF stock rises to $0.70 on 03 Feb 2026: Top PNK gainer, watch low volume

CALZF stock moved to $0.69565 on 03 Feb 2026 during market hours, making PolyNovo Limited (CALZF) one of the top gainers on the PNK exchange in the United States. The quote shows a sharp change from a prior close of $0.00 in available data and very low intraday volume of 33 shares, which amplifies price swings. Traders should note the discrepancy between the trade price and average volume as a key immediate risk for short-term trading.

Price action and volume: CALZF stock movement

CALZF stock recorded a last trade of $0.69565 with a day high of $0.80 and a day low of $0.69565 on PNK in USD. Reported volume was 33 versus an average volume of 2,819, so this move reflects outsized price impact on thin liquidity. One should treat intraday spikes with caution when average daily turnover is small.

Drivers and catalysts: CALZF stock news and company details

PolyNovo Limited (CALZF) sells the NovoSorb biodegradable wound matrix and is developing hernia and islet-implant products, which remain core fundamental catalysts. The company lists an earnings announcement scheduled for 2026-02-20 and ongoing commercial updates on its website, which could drive follow-through volume. For company details and filings see the official site source.

Fundamentals and valuation: CALZF stock financials

CALZF stock shows mixed fundamentals: reported EPS is $0.01, and the full-quote PE is 69.57 with a market cap near $480,584,927.00 on the PNK exchange in the United States. Key ratios include a price average 50 of $0.76 and price average 200 of $0.82, a current ratio of 2.77, and book value per share of $0.12. These metrics point to growth-stage margins but elevated valuation multiples versus device peers.

Technicals and trend: CALZF stock indicators

Technicals for CALZF stock show neutral momentum: RSI is 49.01, MACD histogram near 0.00, and ADX at 10.38 indicating no clear trend. Bollinger band middle is $0.79 and bands range from $0.71 to $0.86, so current price sits near the lower-middle band. Traders focused on technicals should watch a move above $0.79 for near-term confirmation.

Meyka grade and model outlook: CALZF stock rating and forecast

Meyka AI rates CALZF with a score out of 100: 70.10, Grade B+, Suggestion: BUY. This grade factors S&P 500 comparison, sector and industry performance, financial growth, key metrics, forecasts and analyst signals. Meyka AI’s forecast model projects a yearly price of $0.59067, which implies an approximate downside of -15.18% versus the current $0.69565; forecasts are model-based projections and not guarantees. See our internal page for live data Meyka CALZF stock page.

Risks and price targets: CALZF stock outlook and strategy

Key risks for CALZF stock include thin U.S. PNK liquidity, high valuation multiples and clinical or regulatory setbacks for NovoSorb derivatives. Reasonable near-term price targets: conservative $0.50, base $0.80, and bull $1.20 tied to product rollouts and higher volume. Investors should size positions for volatility and monitor the February earnings update closely.

Final Thoughts

CALZF stock’s intraday move to $0.69565 on 03 Feb 2026 places PolyNovo Limited among the top PNK gainers for the session, but the trade is driven by extremely low volume of 33 shares. Fundamentals show modest profitability with EPS $0.01 and elevated PE 69.57, while technicals remain neutral with RSI 49.01. Meyka AI rates CALZF with a score out of 100 at 70.10 (B+, Suggestion: BUY) and our forecast model projects a yearly price of $0.59067, implying roughly -15.18% downside from the current print. That forecast is model-based and not a guarantee. Short-term traders should weigh liquidity risk and await the 2026-02-20 earnings update; longer-term investors should monitor commercial adoption metrics and follow-on clinical data before increasing exposure. Meyka AI provides this as an AI-powered market analysis platform for context, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.